NCT04801329View on ClinicalTrials.gov

Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

Active, not recruitingOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Interventions
DRUG

Vyndamax (tafamidis 61mg)

As prescribed in real world practice

Trial Locations (1)

Unknown

Pfizer, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY